No EU Fast Track for AZ’s Imfinzi In Stage III Lung Cancer

AstraZeneca will be disappointed at the European Medicines Agency’s refusal of its request for accelerated assessment of Imfinzi in earlier-stage lung cancer as the company is aiming to take hold of this new indication and run with it.

Darts
AstraZeneca missed its target of getting EU speedy review for Infimzi • Source: Shutterstock

AstraZeneca has been refused eventual accelerated assessment in the EU of its PD-L1 blocker, Imfinzi (durvalumab), for stage III lung cancer. This a disappointment for the company, which is keen to get Imfinzi approved as soon as it can for use in patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy – a population where it leads its competitors.

AstraZeneca PLC to date seems not to have filed for approval in the EU for Imfinzi in any indication....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer